Literature DB >> 8061280

L-dopa increases nigral production of hydroxyl radicals in vivo: potential L-dopa toxicity?

T S Smith1, W D Parker, J P Bennett.   

Abstract

Dopamine (DA) deficiency in Parkinson's disease is commonly treated with L-dihydroxyphenylalanine (L-dopa), the amino acid precursor to DA. L-dopa is neurotoxic in vitro and impairs survival of metabolically stressed neurons in vivo. We examined with microdialysis of substantia nigra in awake rats the local production of hydroxyl (OH) radicals before and after systemic L-dopa. We found a dose-dependent increase in OH radical output which paralleled the rate of dopa catabolism, was not blocked by deprenyl, and was increased further by acute inhibition of mitochondrial complex I activity. Following high L-dopa doses, catabolism of dopa-derived DA can exceed capacity of nigral mechanisms to reduce formation of or detoxify free radicals.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8061280     DOI: 10.1097/00001756-199404000-00039

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  15 in total

1.  Inflammatory effects of highly pathogenic H5N1 influenza virus infection in the CNS of mice.

Authors:  Haeman Jang; David Boltz; Jennifer McClaren; Amar K Pani; Michelle Smeyne; Ane Korff; Robert Webster; Richard Jay Smeyne
Journal:  J Neurosci       Date:  2012-02-01       Impact factor: 6.167

2.  The effects of pergolide on memory and oxidative stress in a rat model of Parkinson's disease.

Authors:  Alin Ciobica; Zenovia Olteanu; Manuela Padurariu; Lucian Hritcu
Journal:  J Physiol Biochem       Date:  2011-10-18       Impact factor: 4.158

Review 3.  Laboratory approach to mitochondrial diseases.

Authors:  D Parra; A González; C Mugueta; A Martínez; I Monreal
Journal:  J Physiol Biochem       Date:  2001-09       Impact factor: 4.158

4.  Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease.

Authors:  G Walkinshaw; C M Waters
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

Review 5.  Levodopa in Parkinson's disease: neurotoxicity issue laid to rest?

Authors:  M G Murer; R Raisman-Vozari; O Gershanik
Journal:  Drug Saf       Date:  1999-11       Impact factor: 5.606

Review 6.  Does levodopa accelerate Parkinson's disease?

Authors:  T Simuni; M B Stern
Journal:  Drugs Aging       Date:  1999-06       Impact factor: 3.923

7.  DJ-1 deficiency in astrocytes selectively enhances mitochondrial Complex I inhibitor-induced neurotoxicity.

Authors:  Steven J Mullett; David A Hinkle
Journal:  J Neurochem       Date:  2011-01-28       Impact factor: 5.372

8.  Levodopa slows progression of Parkinson's disease: external validation by clinical trial simulation.

Authors:  Phylinda L S Chan; John G Nutt; Nicholas H G Holford
Journal:  Pharm Res       Date:  2007-02-17       Impact factor: 4.200

9.  Methamphetamine-induced TNF-alpha gene expression and activation of AP-1 in discrete regions of mouse brain: potential role of reactive oxygen intermediates and lipid peroxidation.

Authors:  Govinder Flora; Yong Woo Lee; Avindra Nath; William Maragos; Bernhard Hennig; Michal Toborek
Journal:  Neuromolecular Med       Date:  2002       Impact factor: 3.843

10.  Enhanced toxicity to the catecholamine tyramine in polyglutamine transfected SH-SY5Y cells.

Authors:  Rebecca R Smith; Edgardo R Dimayuga; Jeffrey N Keller; William F Maragos
Journal:  Neurochem Res       Date:  2005-04       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.